We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tricida

News List

US FDA denies approval for Tricida’s Veverimer expresspharma
August 26, 2020
Veverimer (TRC101), a non-absorbed, orally-administered polymer, is designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet drugs
June 28, 2019
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed ...
Tricida files for $150M IPO to fund kidney disease drug approval fiercebiotech
June 11, 2018
Tricida has filed to raise $150 million to bring a chronic kidney disease drug to market. Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up the 80- to 100-person sales team it wants to commercialize
Tricida Announces $100 Million Venture Debt Financing From Hercules Capital biospace
March 05, 2018
Tricida, Inc. announced today that it has entered into a $100 million venture debt facility with Hercules Capital, Inc.